Spots Global Cancer Trial Database for Recurrent High Grade Glioma Treated by LITT
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Recurrent High Grade Glioma Treated by LITT
Official Title: Randomized Clinical Trial of Efficiency and Safety of Recurrent High Grade Glioma Treated by Laser Interstitial Thermal Therapy
Study ID: NCT06161610
Conditions
Study Description
Brief Summary: This clinical trial aims to investigate the efficiency and safety of laser interstitial thermal therapy (LITT) in recurrent high-grade glioma (rHGG) patients. The main questions it aims to answer are: * The LITT would increase the progression-free survival and overall survival of rHGG patients compared to other treatments. * The LITT is safe and applicable to rHGG patients Participants will be randomized to the intervention group (LITT) or control group at a ratio of 2:1. The intervention group patients will receive LITT. The control group will be treated with any other treatment. The primary outcome of this trial is progression-free survival. The estimated sample size is 135, 90 in the LITT group and 45 in the control group.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Tiantan Hospital, Beijing, Beijing, China
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
The First Hospital of Jilin University, Changchun, Jilin, China
Qilu Hospital, Jinan, Shandong, China
Huashan Hospital, Shanghai, Shanghai, China
Contact Details
Name: Tao Jiang, MD
Affiliation: Beijing Tiantan Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
